Camber Capital Management LP Puma Biotechnology, Inc. Transaction History

Camber Capital Management LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.29 - $7.4 $4.95 Million - $8.55 Million	-1,155,000 Reduced 41.18%	1,650,000 $8.75 Million
Q4 2023 Feb 14, 2024	SELL	$2.23 - $4.49 $3.19 Million - $6.42 Million	-1,430,000 Reduced 33.77%	2,805,000 $12.1 Million
Q2 2022 Aug 15, 2022	BUY	$1.64 - $3.3 $385,400 - $775,500	235,000 Added 5.88%	4,235,000 $12.1 Million
Q1 2022 May 16, 2022	BUY	$2.13 - $3.24 $4.15 Million - $6.32 Million	1,950,000 Added 95.12%	4,000,000 $11.5 Million
Q4 2021 Feb 14, 2022	SELL	$2.85 - $6.58 $3.92 Million - $9.05 Million	-1,375,000 Reduced 40.15%	2,050,000 $6.23 Million
Q3 2021 Nov 15, 2021	BUY	$6.63 - $9.39 $4.64 Million - $6.57 Million	700,000 Added 25.69%	3,425,000 $24 Million
Q2 2021 Aug 16, 2021	BUY	$8.98 - $11.6 $1.53 Million - $1.97 Million	170,000 Added 6.65%	2,725,000 $25 Million
Q3 2020 Nov 16, 2020	BUY	$9.5 - $11.14 $1.47 Million - $1.73 Million	155,000 Added 6.46%	2,555,000 $25.8 Million
Q2 2020 Aug 14, 2020	BUY	$7.01 - $13.24 $3.15 Million - $5.96 Million	450,000 Added 23.08%	2,400,000 $25 Million
Q1 2020 May 15, 2020	BUY	$6.28 - $14.57 $12.2 Million - $28.4 Million	1,950,000 New	1,950,000 $16.5 Million
Q1 2019 May 15, 2019	SELL	$20.77 - $42.37 $27 Million - $55.1 Million	-1,300,000 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$20.07 - $46.7 $11 Million - $25.7 Million	550,000 Added 73.33%	1,300,000 $26.5 Million
Q3 2018 Nov 14, 2018	BUY	$41.2 - $59.85 $30.9 Million - $44.9 Million	750,000 New	750,000 $34.4 Million

102

29.1M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $128M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.